SB 623

Drug Profile

SB 623

Alternative Names: Modified bone marrow derived mesenchymal stem cells - SanBio; SB623

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator SanBio
  • Developer SanBio; Sumitomo Dainippon Pharma; Teijin
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain injuries; Stroke
  • Preclinical Parkinson's disease; Retinal disorders; Spinal cord injuries

Most Recent Events

  • 21 Sep 2016 Phase-II clinical trials in Brain injuries (In adults, In the elderly) in Japan (Intracerebral)
  • 08 Sep 2016 SanBio has patent protection for SB 623 in Australia
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Intracerebral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top